Drawing for ZYGEL

USPTO serial 88291596

ZYGEL

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
SMIGA, HOWARD
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with ZYGEL?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Sarah Anne Keefe

Sarah Anne Keefe WOMBLE BOND DICKINSON (US) LLP470 Atlantic Avenue, Suite 600Independence WharfBOSTON, MA 02210

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations for the treatment of human and veterinary diseases and disorders, namely, addiction, auditory diseases and disorders, autism, autoimmune diseases and disorders, anxiety, bone diseases and disorders, cardiovascular diseases and disorders, cardiopulmonary diseases and disorders, cognitive diseases and disorders, dermatological diseases and disorders, diabetic diseases and disorders, endocrine diseases and disorders, gastroenterological diseases and disorders, genetic diseases and disorders, genitourinary diseases and disorders, hepatological diseases and disorders, hormonal diseases and disorders, infectious diseases and disorders, immunological diseases and disorders, inflammatory diseases and disorders, metabolic diseases and disorders, movement diseases and disorders, muscular diseases and disorders, musculoskeletal diseases and disorders, neurodegenerative diseases and disorders, neurodevelopmental diseases and disorders, oncological diseases and disorders, ophthalmic diseases and disorders, pain, post-traumatic stress, pulmonary diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, rheumatological diseases and disorders, psychiatric diseases and disorders, seizure diseases and disorders, sexual dysfunction, speech disorders and diseases, traumatic brain injury, and viral diseases and disorders; Pharmaceutical preparations for the treatment of fragile x syndrome, substance related addiction, autism and autism spectrum disorders, epilepsy, seizure diseases and disorders, anxiety, aphasias, stuttering, post-traumatic stress disorder; all of the foregoing specifically excluding narcolepsy and management of sleep disorders and all of the foregoing solely derived from manufactured synthetic cannabidiol and which do not contain delta-9 tetrahydrocannabinol (THC)ACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Sep 11, 2023MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Sep 11, 2023ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Feb 23, 2023EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Feb 22, 2023EX5GSOU EXTENSION 5 GRANTED—
Feb 22, 2023AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Feb 6, 2023EXT5SOU EXTENSION 5 FILED—
Feb 6, 2023EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jun 28, 2022EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jun 24, 2022EX4GSOU EXTENSION 4 GRANTED—
Jun 24, 2022EXT4SOU EXTENSION 4 FILED—
Jun 24, 2022EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Feb 8, 2022EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Feb 4, 2022EX3GSOU EXTENSION 3 GRANTED—
Feb 4, 2022EXT3SOU EXTENSION 3 FILED—
Feb 4, 2022EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jul 13, 2021EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jul 9, 2021EX2GSOU EXTENSION 2 GRANTED—
Jul 9, 2021EXT2SOU EXTENSION 2 FILED—
Jul 9, 2021EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jan 28, 2021EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jan 26, 2021EX1GSOU EXTENSION 1 GRANTED—
Jan 26, 2021EXT1SOU EXTENSION 1 FILED—
Jan 26, 2021EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Aug 11, 2020NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Jun 16, 2020NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jun 16, 2020PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
May 27, 2020NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
May 6, 2020CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
May 6, 2020XAECEXAMINER'S AMENDMENT ENTERED—
May 6, 2020GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
May 6, 2020GNEAEXAMINERS AMENDMENT E-MAILED—
May 6, 2020CNEAEXAMINERS AMENDMENT -WRITTEN—
Mar 12, 2020TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Mar 11, 2020CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Mar 11, 2020TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Sep 17, 2019GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 17, 2019GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 17, 2019CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 16, 2019DOCKASSIGNED TO EXAMINER—
Apr 18, 2019DOCKASSIGNED TO EXAMINER—
Apr 18, 2019DOCKASSIGNED TO EXAMINER—
Apr 17, 2019AMPXPRELIMINARY/VOLUNTARY AMENDMENT - ENTERED—
Apr 9, 2019ALIEASSIGNED TO LIE—
Apr 5, 2019PARITEAS VOLUNTARY AMENDMENT RECEIVED—
Mar 21, 2019MDSCNOTICE OF DESIGN SEARCH CODE E-MAILED—
Feb 28, 2019NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Feb 9, 2019NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance